Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01251289
Other study ID # 09-072
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 2009
Est. completion date September 2010

Study information

Verified date December 2023
Source Unity Health Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A retrospective review of the prevalence of Group B Streptococcus Positive Pregnant Patients in an Inner City Tertiary Care Center


Description:

This is a retrospective chart review of the prevalence of Group B Streptococcus (GBS) positive patients


Recruitment information / eligibility

Status Completed
Enrollment 628
Est. completion date September 2010
Est. primary completion date September 2010
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria: - GBS positive pregnant women Exclusion Criteria: - n/a

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Unity Health Toronto
See also
  Status Clinical Trial Phase
Recruiting NCT04059510 - Developing a Controlled Human Infection Model for Group B Streptococcus (CHIM_GBS)
Completed NCT01150123 - Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women Phase 1
Completed NCT02511444 - Intrapartum Rapid GBS Testing in Patients Presenting With Threatened Preterm Labor N/A
Completed NCT00716781 - Management of Infants Born to Group B Streptococcus Positive Mothers. N/A
Completed NCT01982084 - Group B Streptococcus: Attitudes to Immunisation in Pregnancy
Active, not recruiting NCT00972894 - Group B Streptococcus (GBS) Polymerase Chain Reaction (PCR) Concordance Study N/A
Terminated NCT00823433 - Oral Penicillin and Penicillin Levels in Venous Umbilical Cord Blood Phase 0
Completed NCT01180023 - Membrane Sweeping in Group B Streptococcus (GBS) Positive Patients N/A
Completed NCT00008853 - Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines Phase 1